Феърфилд
[ ]
Меплазумаб (Meplazumab)
Международное непатентованное наименование Меплазумаб (Meplazumab)
Торговое наименование Ketantin
Производитель, страна Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, China
Механизм действия

Meplazumab (Ketantin®) is a lyophilized powder for injection of small volume. The main active ingredient of the product, meplazumab, is a humanized immunoglobulin (Ig) G2 monoclonal antibody, consisting of the complementary-determining regions of anti CD147 murine antibody and the human framework region. It acts as an erythrocytic stage-macromolecular antibody drug that has the potential to mediate both treatment and prophylaxis of falciparum malaria.

Публикации COVID-19
Huijie BianZhao-Hui Zheng, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. DOI: 10.1101/2020.03.21.20040691. 
Клинические исследования
1.
Название протокола Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
Дата начала и окончания КИ February 3, 2020 - December 31, 2020
Название организации, проводящей КИ Tang-Du Hospital
Страны China
Фаза I-II
Кол-во пациентов 20